THU029 Subcutaneous Self-injections Of Lanreotide Is a Good Alternative For Acromegalic Patients With Long COVID Treated With Anticoagulants

Disclosure: I.N. Rosa: None. L.A. Naves: None. Background: Acromegaly control during pandemics was an important challenge. Telemedicine was a resource to provide health care, associated to electronic prescription sent directly to central pharmacy and drugs delivered to patients' home avoided treatment disruption in 2020 and 2021. The concomitant use of anticoagulants in Covid patients is a major concern because of risk of muscle hematomas. We describe here the replacement of Octreotide LAR to Somatuline Autogel in long Covid acromegalic patients with thromboembolic co-morbidities. Methods: We describe a sample of acromegalic patients, diagnosed with long Covid and thromboembolic co-morbidities. All patients were previously submitted to transsphenoidal surgery for somatotropic tumors and were controlled by mensal injections of octreotide LAR. Outpatient management was remodeled to simplify access to care by (1) adoption of virtual meetings; (2) collection of blood samples at home; (3) abolishment of printed prescription and provision of electronic files directly to central pharmacy; and (4) replacement of intramuscular injections for subcutaneous self injection of Lanreotide- Autogel. Results: From our cohort of 128 acromegalic patients, coronavirus disease (COVID-19) was confirmed in18%, although, long COVID, and use of anticoagulant drugs for more than 4 months was observed in 8 cases, 5 women, median age 68 years. Patients adopted self injections monthly and maintained disease control in 75% of cases with good adherence. Local side-effects, as injection-site pain, equimosis were observed less frequently than reported by the patients in previous use of Octreotide LAR. Conclusion: Telemedicine was a feasible tool in acromegalic patients with Long Covid. The replacement of intramuscular injections of Octreotide LAR for Lanreotide Autogel self injected subcutaneously allowed stability of disease control and provided an alternative to injections administered in the health care Presentation: Thursday, June 15, 2023